000			01979 a2200565 4500
005			20250514183916.0
264		0	_c20041026
008			200410s 0 0 eng d
022			_a1084-9785
024	7		_a10.1089/108497804773391658 _2doi
040			_aNLM _beng _cNLM
100	1		_aBushnell, David
245	0	0	_aEffects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. _h[electronic resource]
260			_bCancer biotherapy & radiopharmaceuticals _cFeb 2004
300			_a35-41 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAmino Acids _xadministration & dosage
650	0	4	_aArginine _xadministration & dosage
650	0	4	_aCarcinoid Tumor _xmetabolism
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aKidney _xdrug effects
650	0	4	_aLung Neoplasms _xmetabolism
650	0	4	_aLysine _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMeningioma _xmetabolism
650	0	4	_aMiddle Aged
650	0	4	_aOctreotide _xadministration & dosage
650	0	4	_aPancreatic Neoplasms _xmetabolism
650	0	4	_aRadiopharmaceuticals _xadministration & dosage
650	0	4	_aYttrium Radioisotopes _xadministration & dosage
700	1		_aMenda, Yusuf
700	1		_aO'Dorisio, Thomas
700	1		_aMadsen, Mark
700	1		_aMiller, Sara
700	1		_aCarlisle, Thomas
700	1		_aSquires, Shayne
700	1		_aKahn, Daniel
700	1		_aWalkner, Wayne
700	1		_aConnolly, Mary
700	1		_aO'Dorisio, Sue
700	1		_aKarwal, Mark
700	1		_aPonto, James
700	1		_aBouterfa, Hakim
773	0		_tCancer biotherapy & radiopharmaceuticals _gvol. 19 _gno. 1 _gp. 35-41
856	4	0	_uhttps://doi.org/10.1089/108497804773391658 _zAvailable from publisher's website
999			_c14784060 _d14784060